“Global Angiography Devices Market is anticipated to reach $18.43bn by 2029”, says Visiongain report

04 September 2019
Pharma

Visiongain has launched a new pharma report Angiography Devices Market Report 2019-2029: By Product Type (Consumables, Angiography System), Technology (X-Ray, CT, MRA), Application (Diagnostics, Therapeutics), Procedure (Coronary Angiography, Micro Angiography, Non Coronary Angiography, Others), Indication (Known Suspected CAD, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart Failure, Others), End User (Hospitals, Diagnostic Centers, Academics & Research Laboratories) and by Region.

The global market for angiography devices is expected to expand due to technological developments, increased application scope, increased awareness programs and financing activities combined with increased demand for interventional angiography systems in minimally invasive surgeries. The global angiography devices market is anticipated to grow at a lucrative CAGR of 6.3% and anticipated to reach USD 18.43 Billion by 2029.

An angiogram is a diagnostic and therapeutic X-ray operation.  It is regarded as the gold standard in the arterial system for assessing blockages. An angiogram detects blockages using X-rays taken when a contrast agent (iodine dye) is injected. The operation offers data that helps the vascular surgeon identify the best choices for therapy. Typically, angiograms are conducted while an individual is in sedation. Depending on how hard the exam is and how much therapy is provided, the operation can last 15-20 minutes or up to several hours.

CT angiography has developed as a consequence of tremendous technological advances to provide significant insights into the diagnosis and management of cardiovascular disease. While many CT angiography applications have transformed the standard for clinical care, CT angiography has extended knowledge of human vascular illness, guiding fresh approaches in disease management and in which new CT techniques offer promise for further refinements.

Cardiovascular diseases have become the major cause of premature death, including heart attacks, strokes, and other circulatory illnesses. Cardiovascular diseases account for nearly 17.3 million fatalities per year, according to the World Health Organization, and this amount is anticipated to increase to over 23.6 million by 2030. As a result, the growing amount of cardiovascular diseases drives demand for angiography devices, which eventually leads to the development of the market for angiography instruments. In addition, other variables such as rapid technological advances, increased population awareness, and the strong preference of minimally invasive processes also complement the development of the industry.

North America holds majority of market share followed by Europe and will continue to dominate in the future as a result of a Growing demand for advanced medical devices, increasing geriatric population, and rising prevalence of CVDs among other prominent factors to boost the growth of regional market. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to changes in government reimbursement policies, growing import from European and U.S. based manufacturers are some of the factors anticipated to boost the growth of Asia Pacific angiography devices market over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global angiography devices market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

For example, in 2017, five new angiography systems were introduced which included changes to speed workflow and enhance image quality as well as procedural guidelines for intervention.

Two of last year's greatest breakthroughs in angiography were the release of new Philips Azurion technologies and Siemens Artis Pheno, both of which won the U.S. FDA clearance in early 2017. "The focus of the Philips Azurion is on incorporating workflow characteristics that assist the doctor without having to go to various opinions, imaging systems or screens. It allows doctors to make choices on the fly and very fast. In addition to those two systems, Canon Medical Systems (formerly Toshiba) and Shimadzu launched sales of two new systems. Siemens also unveiled a CT / MRI angiography system at the 2017 Radiological Society of North America (RSNA) annual meeting.

The comprehensive market report features companies such as Abbott, Accuron Technologies Limited, Allengers, ANGIOCARE, Angiodynamics, AV MEDICAL, B. Braun, Boston Scientific, Canon Medical Systems, Cook Medical Inc., Cordis (A Cardinal Health Company), Forus Health Pvt. Ltd., GE Healthcare, GETINGE AB, Johnson & Johnson Private Limited, LEDVANCE LLC, Medtronic, Philips, Remidio Innovative Solutions Pvt. Ltd., Shimadzu, Siemens, St. Jude Medical, Inc., and Terumo among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever